Search by topic:
British scientists who announced last week their discovery of a new type of cancer-killing T-cell have entered a partnership with Ervaxx, a biotechnology company pioneering the use of Dark Antigens to develop T-cell receptor (TCR)-based immunotherapies and off-the-shelf cancer vaccines. The result—they hope—will be a “one-size-fits-all” cancer therapy.
Jonathan Chrimes